Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 596 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC August 27, 2020 Honoring our Labor September 1, 2021 EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 Load more HOT NEWS Coronavirus reports – Part 9: “I am very relieved but I... The Doctor Will See You Now…On the Screen Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With... New on NCI’s Websites for March 2019
